{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:33:42Z","timestamp":1790400822909,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.metabol.2017.04.010","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T02:00:46Z","timestamp":1493258446000},"page":"109-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-4845","authenticated-orcid":false,"given":"Baris","family":"Akinci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Onay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eenay","family":"Savas-Erdeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Gen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilgin Yildirim","family":"Simsir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Ela","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sercan","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Kubat","family":"Uzum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guzin Fidan","family":"Yaylali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilufer Kutbay","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Atik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samim","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu Sarer","family":"Yurekli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce","family":"Apaydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulcin","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Comlekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Secil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Arioglu","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2017.04.010_bb0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.metabol.2017.04.010_bb0010","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.metabol.2009.03.001","article-title":"Predicting abdominal adipose tissue among women with familial partial lipodystrophy","volume":"58","author":"Joy","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.04.010_bb0015","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jacl.2016.08.012","article-title":"Familial partial lipodystrophy presenting as metabolic syndrome","volume":"10","author":"Chan","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2017.04.010_bb0020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11883-000-0078-0","article-title":"Insulin resistance in human partial lipodystrophy","volume":"2","author":"Hegele","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.metabol.2017.04.010_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.metabol.2014.10.016","article-title":"From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century","volume":"64","author":"Bluher","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.04.010_bb0030","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng0398-292","article-title":"Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21\u201322","volume":"18","author":"Peters","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2017.04.010_bb0035","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2017.04.010_bb0040","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","article-title":"Perilipin deficiency and autosomal dominant partial lipodystrophy","volume":"364","author":"Gandotra","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.04.010_bb0045","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.1096706","article-title":"A family with severe insulin resistance and diabetes due to a mutation in AKT2","volume":"304","author":"George","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.metabol.2017.04.010_bb0050","first-page":"1649","article-title":"A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy","volume":"30","author":"Farhan","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.metabol.2017.04.010_bb0055","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/emmm.200900037","article-title":"Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC","volume":"1","author":"Rubio-Cabezas","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.metabol.2017.04.010_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat Methods"},{"key":"10.1016\/j.metabol.2017.04.010_bb0065","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2009.86","article-title":"Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm","volume":"4","author":"Kumar","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.metabol.2017.04.010_bb0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.metabol.2017.04.010_bb0075","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/nar\/gkp215","article-title":"Human splicing finder: an online bioinformatics tool to predict splicing signals","volume":"37","author":"Desmet","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2017.04.010_bb0080","first-page":"S4","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.04.010_bb0085","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"Suppl. 5","key":"10.1016\/j.metabol.2017.04.010_bb0090","first-page":"S213","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.metabol.2017.04.010_bb0095","first-page":"2127","volume":"45","year":"1992","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.metabol.2017.04.010_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejim.2015.12.012","article-title":"A case of familial partial lipodystrophy caused by a novel lamin A\/C (LMNA) mutation in exon 1 (D47N)","volume":"29","author":"Kutbay","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.metabol.2017.04.010_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/dme.13061","article-title":"Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor-gamma (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A\/C (LMNA) mutations","author":"Demir","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2017.04.010_bb0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/505885","article-title":"Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy","volume":"79","author":"Hegele","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2017.04.010_bb0115","first-page":"59","article-title":"Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a\/c gene","volume":"86","author":"Garg","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.04.010_bb0120","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.2337\/diabetes.49.11.1958","article-title":"Lamin A\/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy","volume":"49","author":"Vigouroux","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2017.04.010_bb0125","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1210\/jc.2007-0654","article-title":"New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome","volume":"92","author":"Decaudain","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.04.010_bb0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2265.2007.03146.x","article-title":"A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy","volume":"69","author":"Araujo-Vilar","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.04.010_bb0135","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-12-0268","article-title":"Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations","volume":"167","author":"Mory","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.04.010_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000354716","article-title":"Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA","volume":"124","author":"Thong","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.metabol.2017.04.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1111\/cen.13311","article-title":"Spectrum of disease associated with partial lipodystrophy (PL): lessons from a trial cohort","author":"Ajluni","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.04.010_bb0150","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00125-004-1360-4","article-title":"Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene","volume":"47","author":"Savage","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2017.04.010_bb0155","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-011-2142-4","article-title":"Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARgamma mutation (Y151C)","volume":"54","author":"Visser","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2017.04.010_bb0160","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/ng.3700","article-title":"Prospective functional classification of all possible missense variants in PPARG","volume":"48","author":"Majithia","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2017.04.010_bb0165","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/diabetes.52.4.910","article-title":"Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma","volume":"52","author":"Savage","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2017.04.010_bb0170","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1515\/jpem-2012-0007","article-title":"A Chinese patient with acquired partial lipodystrophy caused by a novel mutation with LMNB2 gene","volume":"25","author":"Gao","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.04.010_bb0175","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00439-013-1331-2","article-title":"Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease","volume":"132","author":"Cooper","year":"2013","journal-title":"Hum Genet"},{"key":"10.1016\/j.metabol.2017.04.010_bb0180","doi-asserted-by":"crossref","first-page":"e91987","DOI":"10.1371\/journal.pone.0091987","article-title":"Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy","volume":"9","author":"Karlas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2017.04.010_bb0185","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J Diabetes Metab"},{"key":"10.1016\/j.metabol.2017.04.010_bb0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ecl.2016.04.012","article-title":"Leptin and hormones: energy homeostasis","volume":"45","author":"Triantafyllou","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.metabol.2017.04.010_bb0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.metabol.2014.07.017","article-title":"Leptin in congenital and HIV-associated lipodystrophy","volume":"64","author":"Tsoukas","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.04.010_bb0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/er.2012-1053","article-title":"Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals","volume":"34","author":"Moon","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2017.04.010_bb0205","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4093\/dmj.2012.36.3.181","article-title":"Leptin in relation to the lipodystrophy-associated metabolic syndrome","volume":"36","author":"Mantzoros","year":"2012","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2017.04.010_bb0210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrendo.2010.199","article-title":"Lipodystrophy: pathophysiology and advances in treatment","volume":"7","author":"Fiorenza","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2017.04.010_bb0215","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.metabol.2012.04.013","article-title":"Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: a need for more mechanistic studies and large, randomized, placebo-controlled trials","volume":"61","author":"Foo","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.04.010_bb0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2016","journal-title":"Nat Genet"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:14:03Z","timestamp":1758428043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517301245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":44,"alternative-id":["S0026049517301245"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.04.010","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}